Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.05 CAD | -0.06% | -1.09% | -1.84% |
May. 17 | Tranche Update on BioSyent Inc. (TSXV:RX)'s Equity Buyback Plan announced on December 13, 2023. | CI |
May. 17 | BioSyent Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 35M 25.65M | Sales 2025 * | 38.7M 28.36M | Capitalization | 107M 78.2M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 3.05 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.76 x |
P/E ratio 2024 * |
16.5
x | P/E ratio 2025 * |
14.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 60.63% |
Latest transcript on BioSyent Inc.
1 day | -0.06% | ||
1 week | -1.09% | ||
1 month | +4.14% | ||
3 months | +6.35% | ||
6 months | +6.60% | ||
Current year | -1.84% |
Managers | Title | Age | Since |
---|---|---|---|
René C. Goehrum
CEO | Chief Executive Officer | 64 | 95-12-31 |
Robert March
DFI | Director of Finance/CFO | - | 18-09-09 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 14-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sara Elford
BRD | Director/Board Member | 53 | 18-01-07 |
René C. Goehrum
CEO | Chief Executive Officer | 64 | 95-12-31 |
Peter Lockhard
BRD | Director/Board Member | 60 | 02-05-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 9.05 | -0.55% | 20,401 |
24-05-30 | 9.1 | -2.36% | 23,235 |
24-05-29 | 9.32 | +0.76% | 11,950 |
24-05-28 | 9.25 | +1.65% | 6,485 |
24-05-27 | 9.1 | -0.55% | 10,200 |
Delayed Quote Toronto S.E., May 31, 2024 at 03:58 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.84% | 78.21M | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- RX Stock